Diatech Pharmacogenetics, an Italian supplier of molecular tests for cancer precision medicine, announced on Wednesday that it is expanding its collaboration with Merck Serono Middle East Ltd, an affiliate of German science and technology company Merck KGaA (ETR:MRK), to improve access to RAS biomarker testing for colorectal cancer patients in the Middle East and Africa.

This collaboration aims to enhance personalised medicine by providing physicians with crucial information to guide treatment decisions.

Diatech Pharmacogenetics offers a CE-IVD diagnostic solution that enables rapid and accurate assessment of key biomarkers, including KRAS, BRAF and NRAS mutations, in colorectal cancer patients.